BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
 | Browse: 419 | Download: 565
Publication Name World Journal of Ophthalmology
Manuscript ID 16150
Country/Territory
Received
2014-12-30 09:23
Peer-Review Started
2014-12-30 20:15
To Make the First Decision
2015-01-20 13:29
Return for Revision
2015-02-03 20:20
Revised
2015-02-21 07:34
Second Decision
2015-04-26 20:08
Accepted by Journal Editor-in-Chief
2015-04-27 04:41
Accepted by Company Editor-in-Chief
2015-05-06 14:17
Articles in Press
2015-05-06 14:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-07-18 18:15
Publish the Manuscript Online
2015-08-17 11:09
ISSN 2218-6239 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Ophthalmology
Manuscript Type Editorial
Article Title Approved pharmacotherapy for macular edema secondary to branch retinal vein occlusion: A review of randomized controlled trials in dexamethasone implants, ranibizumab, and aflibercept
Manuscript Source Invited Manuscript
All Author List Jia-Kang Wang
Funding Agency and Grant Number
Corresponding Author Dr. Jia-Kang Wang, MD, Department of Ophthalmology, Far Eastern Memorial Hospital, 21, Sec. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei City, Taipei 220, Taiwan. jiakangw@yahoo.com.tw
Key Words Branch retinal vein occlusion; Intravitreal injection; Aflibercept; Ranibizumab; Macular edema; Ozurdex
Core Tip There are three approved pharmacotherapies for treating macular edema secondary to branch retinal vein occlusion (BRVO), including corticosteroids (dexamethasone implants) and anti-vascular endothelial growth factor (VEGF) (ranibizumab and aflibercept). They all show superior ability to improve vision and reduce macular thickness, comparing with sham injections or macular grid laser treatment. There is no severe ocular or systemic adverse reaction reported in studies associated with anti-VEGF for macular edema after BRVO. Intraocular pressure elevation and cataract aggravation should be addressed after intravitreal dexamethasone implants. Single intravitreal dexamethasone implant had longer effective duration than two anti-VEGFs.
Publish Date 2015-08-17 11:09
Citation Wang JK. Approved pharmacotherapy for macular edema secondary to branch retinal vein occlusion: A review of randomized controlled trials in dexamethasone implants, ranibizumab, and aflibercept. World J Ophthalmol 2015; 5(3): 106-109
URL http://www.wjgnet.com/2218-6239/full/v5/i3/106.htm
DOI http://dx.doi.org/10.5318/wjo.v5.i3.106
Full Article (PDF) WJO-5-106.pdf
Full Article (Word) WJO-5-106.doc
Manuscript File 16150-Review.doc
Answering Reviewers 16150-Answering reviewers.pdf
Audio Core Tip 16150-Audio core tip.wav
Conflict-of-Interest Disclosure Form 16150-Conflict-of-interest statement.pdf
Copyright License Agreement 16150-Copyright assignment.pdf
Institutional Review Board Approval Form or Document 16150-Journal editor-in-chief review report.pdf
Peer-review Report 16150-Peer-review(s).pdf
Scientific Misconduct Check 16150-Scientific misconduct check.pdf
Scientific Editor Work List 16150-Scientific editor work list.pdf